NeuroBlu
Real-world data platform of de-identified behavioural-health and neurology patient records, with a web application and an analytics workspace in R, Python or SQL.
neuroblu.aiAt a glance
- Type
- SaaS
- Platforms
- Web
- Who it’s for
- Payers, pharma and researchers
- Sources cited
- 2
- In the library since
- 24 September 2026
What it does
Holmusk describes NeuroBlu as research-grade real-world data from drug discovery to patient care delivery, with a web application and an analytics workspace in which users run analyses in R, Python or SQL; its site gives 46,500,000 patients. In May 2026 the company released version 26R2, adding two neurological health systems, Alzheimer's disease biomarker data, claims linkage and neuroimaging encounter data (company release).
Pricing is not published. It carries no regulatory status.
Similar products
Castor EDC
Electronic data capture system for clinical trials, with eCOA, ePRO and eConsent add-ons, sold to device, biopharma, diagnostics and academic research teams.
Research TechnologyWebSeqOneSeqOne Platform
Laboratory genomic analysis platform for oncology, inherited and infectious disease, with the DiagAI variant-prioritisation model; IVDR Class C certified by GMED, according to the company.
GenomicsWebSOPHiA GENETICS
SOPHiA DDM
Genomic analysis platform that calls, annotates and pre-classifies variants from sequencing data for clinical teams.
GenomicsWebAPIWaystarWaystar Platform
Cloud revenue cycle platform covering financial clearance, claims and payer payments, patient payments, denial recovery and analytics, with AI features the company markets as Waystar AltitudeAI.
Revenue CycleWeb